Cefuroxime
Zinnat is an antibiotic used in adults and children. The medicine works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins.
Zinnat may also be used:
Your doctor may test what type of bacteria caused your infection and check if the bacteria are sensitive to Zinnat during treatment.
Before taking Zinnat, discuss it with your doctor or pharmacist.
Zinnat is not recommended for children under 3 monthsbecause the safety and efficacy of the medicine in this age group are not known.
During treatment with Zinnat, pay attention to whether the following symptoms occur: allergic reactions, fungal infections (e.g., thrush), and severe diarrhea (pseudomembranous colitis). This will reduce the risk of complications. See "Symptoms to watch out for" in section 4.
Zinnat may affect the results of blood sugar tests and a blood test called the Coombs test. If you are going to have a blood test, you should:
Tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, as well as any medicines you plan to take.
Zinnat may reduce the effectiveness of oral contraceptives. If you are taking oral contraceptives while taking Zinnat, you should also use mechanical methods of contraception(e.g., condoms). If you have any doubts, consult your doctor.
If you are pregnant, breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before taking this medicine.
Zinnat may cause dizzinessand other side effects that may impair your alertness.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are unsure, consult your doctor or pharmacist again.
Zinnat is available in the following strengths: 125 mg, 250 mg, 500 mg.
Take Zinnat after a meal. This will help increase the effectiveness of the treatment.
Swallow the Zinnat tablets whole with water.
Do not chew, crush, or break the tablets- this may reduce the effectiveness of the treatment.
The recommended dose of Zinnat is 250 mg to 500 mg twice a day, depending on the severity and type of infection.
The recommended dose of Zinnat is 10 mg/kg body weight (not more than 125 mg) to 15 mg/kg body weight (not more than 250 mg) twice a day, depending on the severity and type of infection.
Zinnat is not recommended for children under 3 monthsbecause the safety and efficacy of the medicine in this age group are not known.
Depending on the disease and how the patient responds to treatment, the initial dose may be changed or more than one treatment cycle may be necessary.
If you have kidney problems, your doctor may change the dose of Zinnat.
If you take more Zinnat than recommended, you may experience neurological disorders, particularly an increased risk of seizures(epileptic fits).
Do not take a double dose to make up for a missed dose. Take the next dose at the usual time.
It is important not to shorten the prescribed treatment period with Zinnat. Do not stop treatment without your doctor's advice, even if you feel better. Shortening the recommended treatment period may lead to a recurrence of the disease.
If you have any further doubts about taking this medicine, consult your doctor or pharmacist.
Like all medicines, Zinnat can cause side effects, although not everybody gets them.
A small number of people taking Zinnat have reported an allergic reaction or potentially severe skin reaction. The symptoms may be:
May affect up to 1 in 10 people:
Common side effects that may be seen in blood tests:
May affect up to 1 in 100 people:
Uncommon side effects that may be seen in blood tests:
Other side effects occur in a very small number of patients, but the exact frequency is unknown:
Side effects that may be seen in blood tests:
If you experience any side effects, including any not listed in this leaflet, tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Medicinal Product Monitoring, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warszawa, tel.: + 48 22 49 21 301, fax: + 48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
Store in a temperature below 30°C, in the original packaging.
Do not use if the tablets are crushed or damaged in any way.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
The active substance is cefuroxime: each film-coated tablet contains 500 mg of cefuroxime in the form of cefuroxime axetil.
The other ingredients are: microcrystalline cellulose, sodium croscarmellose, sodium lauryl sulfate, hydrogenated vegetable oil, anhydrous colloidal silica; coating: hypromellose, propylene glycol, methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), Opaspray White M-1-7120 J (containing, among others, titanium dioxide (E 171) and sodium benzoate (E 211)).
Zinnat 500 mg film-coated tablets are white, capsule-shaped, smooth on one side, and have "GX EG2" embossed on the other.
The tablets are packaged in PA/Al/PVC//Al blisters in a cardboard box. The packs contain 10, 20, or 50 film-coated tablets.
For more detailed information, consult the marketing authorization holder or parallel importer.
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
GlaxoSmithKline Trading Services Limited
12 Riverwalk
Citywest Business Campus
Dublin 24
Ireland
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Croatia, the country of export:HR-H-565616124-01
Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Romania, Slovakia, Slovenia, Spain, United Kingdom – Zinnat
Germany – Elobact
Greece – Zinadol
Italy – Oraxim
Portugal – Zipos
Portugal – Zoref
Date of revision of the leaflet: 11.01.2023
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.